|
J Biol Chem, Vol. 274, Issue 51, 36592-36600, December 17, 1999
Identification and Characterization of cvHsp
A NOVEL HUMAN SMALL STRESS PROTEIN SELECTIVELY EXPRESSED IN
CARDIOVASCULAR AND INSULIN-SENSITIVE TISSUES*
Stéphane
Krief §,
Jean-François
Faivre ,
Philippe
Robert ,
Bertrand
Le Douarin ¶ ,
Nicole
Brument-Larignon ,
Isabelle
Lefrère ,
Mark M.
Bouzyk**,
Karen
M.
Anderson ,
Larry D.
Greller ,
Frank L.
Tobin ,
Michel
Souchet , and
Antoine
Bril
From SmithKline Beecham Laboratoires Pharmaceutiques,
4 rue du Chesnay-Beauregard, BP 58, 35762 Saint-Grégoire,
France, the CNRS Unité Propre 041, Rennes, France,
** SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, CM19
5AD Harlow, United Kingdom, and  SmithKline
Beecham Pharmaceuticals,
King of Prussia, Pennsylvania 19406-0939
 |
ABSTRACT |
Starting with computational tools that search for
tissue-selective expression of assembled expressed sequenced tags, we
have identified by focusing on heart libraries a novel small stress protein of 170 amino acids that we named cvHsp. cvHsp was
found as being computationally selectively and highly (0.3% of the
total RNA) expressed in human heart. The cvHsp gene mapped
to 1p36.23-p34.3 between markers D1S434 and
D1S507. The expression of cvHsp was analyzed
with RNA dot, Northern blots, or reverse transcription-polymerase chain
reaction: expression was high in heart, medium in skeletal muscle, and
low in aorta or adipose tissues. In the heart of rat models of cardiac
pathologies, cvHsp mRNA expression was either unchanged
(spontaneous hypertension), up-regulated (right ventricular hypertrophy
induced by monocrotaline treatment), or down-regulated (left
ventricular hypertrophy following aortic banding). In obese Zucker
rats, cvHsp mRNA was increased in skeletal muscle,
brown, and white adipose tissues but remained unchanged in the heart. Western blot analysis using antipeptide polyclonal antibodies revealed
two specific bands at 23 and 25 kDa for cvHsp in human heart. cvHsp
interacted in both yeast two-hybrid and immunoprecipitation experiments
with -filamin or actin-binding protein 280. Within cvHsp, amino acid
residues 56-119 were shown to be important for its specific
interaction with the C-terminal tail of -filamin.
 |
INTRODUCTION |
Not only heat shock but also diverse stresses, including heavy
metals, amino acid analogues, inflammation, and oxidative/ischemic stress, up-regulate the rapid synthesis of a multigene family of
proteins, originally called heat shock proteins
(Hsps)1 (reviewed in Refs. 1
and 2). Hsps are mostly chaperones that associate with malfolded
proteins, prevent their aggregation into large damaging complexes, aid
their renaturation, and influence the final intracellular location of
mature proteins. The Hsp superfamily comprises several subfamilies,
including Hsp70, Hsp90 or Hsp110, the mitochondrial Hsp60/Hsp10 and
cytosolic (t-complex polypeptide-1 (TCP-1) ring complex) chaperonin
systems, and the low molecular weight heat shock or small stress
proteins (smHsps), including B-crystallin, A-crystallin, Hsp20
protein, Hsp -2, Hsp-like 27, and Hsp27 (reviewed in Ref. 1). The
presence of an evolutionarily conserved -crystallin domain
characterizes all smHsps. This domain is preceded by an N-terminal
domain, which is variable in size and sequence, and is followed by a
short, poorly conserved C-terminal extension, known to undergo numerous
modifications including truncations (3). The smHsp family of proteins
have since been shown to play a role in stabilizing protein folding and
transport and chiefly through the modulation of actin polymerization
and cytoskeletal organization. B-crystallin interacts with actin,
desmin, and vimentin in the heart (4, 5); Hsp27 interacts with actin and platelet factor XIII (6, 7). More recently, Hsp -2, also called
MKBP, was shown to bind and activate myotonic dystrophy protein kinase
in the yeast two-hybrid system (8). All of these smHsps have been shown
to be highly expressed in muscular tissues, including the heart
(e.g. see Ref. 8 and references therein).
Gene discovery using expressed sequence tag (EST) data bases has proved
a powerful alternative to experimental cloning techniques (e.g. filter hybridization, PCR using degenerate primers,
etc.) and is thought to provide a rapid route to identifying and
mapping the great majority of the 65,000-80,000 genes in the human
genome (9). Initial approaches for data base cloning most often rely on
sequence homologies searches for paralogs or orthologs with nucleotide
or protein queries using the BLAST or FASTA algorithms (10). Other
strategies are based on the use of keywords queries on sequence
annotations, and an example includes a text-based search to find new
sequences that shared homology with ion channels (11). Similarly, a
strategy based on the use of the word "prost" (for prostate) as
query for EST data bases lead to the finding of three contigs (assembly
of overlapping ESTs) selectively expressed in this organ (12).
In the present study, we augmented such strategies by using a novel
computational approach aimed at identifying "selectively expressed"
genes in chosen cDNA libraries (EST data bases) (13). This method
was applied to heart cDNA libraries and allowed the identification
of a novel smHsp, cvHsp, selectively expressed in
cardiovascular and insulin-sensitive tissues. We report here initial
characterization of cvHsp, including molecular cloning, chromosome localization, mRNA distribution in normal and
pathological states, and the interaction of cvHsp with -filamin, or
actin-binding protein 280 (14).
 |
EXPERIMENTAL PROCEDURES |
Electronic Identification of a Tissue-selective Gene--
A
computational method has been developed to identify gene products
selectively expressed in a particular tissue when compared against
expression levels in other tissues (13). Briefly, the algorithm
identifies these exceptional levels of expression by combining a
statistical test of discordancy with adjustments for the separation of
the largest from the next-to-largest intensity. In addition, the
algorithm estimates its own reliability in order to distinguish high
confidence calculations from more ambiguous ones. The algorithm has
been implemented to routinely analyze large data bases of gene
abundances. The method was applied to cardiac libraries and allowed the
identification of assembled ESTs highly and selectively expressed in
the heart.
Cloning of cvHsp--
Several 5' clones of the assembly
corresponding to cvHsp were requested and fully sequenced on
both strands using an ABI automatic sequencer. 5'-Rapid amplification
of cDNA ends experiments were performed using the Marathon Ready
human heart cDNA (CLONTECH). The
following primers were used: 5'-CCGCTCGGAAGGTGGAAGAGGTTCT-3' and
5'-CGAGGGCTGGACAGGAGAGGGTGTG-3' for the ACD transcript (see "Results" and Fig. 2, panel 3), for the initial PCR and
the second nested PCR, respectively, using the protocol recommended by
the manufacturer. Similarly, 5'-CCTCCTCATTCCTACAGCCCACCTT-3' and
5'-CCCCAGGGCCACAACTGTTCCTTAG-3' were used for the initial PCR and
the second nested PCR, respectively, for the alternative ABCD form (see
under "Results" and Fig. 2). Double stranded amplification products
were then sequenced. The mouse ortholog of human cvHsp was
found by homology searches in dbEST, and its sequence was further
confirmed after RT-PCR amplification of the mRNA from mouse heart.
The rat sequence was amplified using primers defined for the mouse.
Sequences of cvHsp from human, mouse, and rat have been
deposited in the GenBankTM/EMBL data bases.
RNA Analysis--
Total RNA was extracted using the acid
guanidinium thiocyanate-phenol-chloroform method (15). RT-PCR was
performed using Moloney murine leukemia virus reverse transcriptase
(Life Technologies, Inc.) and Taq DNA polymerase (Promega)
as described previously (16) in a PTC-200 Thermal Cycler (MJ Research).
The sequences of the primers were as follows: 5'-CGCCCACACCCTCTCCT-3'
(sense) and 5'-CTTCTCAGCCCGCACCTC-3' (antisense) for cvHsp,
and 5'-TCGTGTGCACCGTGTGGGCC-3' (sense) and
5'-AGGAAACGGCGCTCGCAGCTGTCG-3' (antisense) for 1-adrenergic receptor. The expected size of the amplicons were 412 bp for
cvHsp and 265 bp for 1-adrenergic receptor.
Northern blot analysis was done either on 10 µg of total RNA or on 2 µg of poly(A)+ RNA using standard methods (17). A prenormalized
50-tissue poly(A)+ RNA dot blot was used to semiquantitatively assess
cvHsp expression (Human RNA Master Blot,
CLONTECH). Blots were exposed to x-ray films for
2-12 h. Densitometric analyses were performed for cvHsp and
the ubiquitin normalization probe.
Yeast Two-hybrid Analyses--
The plasmids pHybLex/Zeo and
pAS2-1 were purchased from Invitrogen and CLONTECH
(Matchmaker system 2), respectively. The complete open reading frame of
cvHsp (170 amino acids), and derivatives thereof (amino
acids 41-170, 56-170, and 119-170) were fused to the LEXA
DNA-binding domain after PCR amplification from human heart cDNA
(Invitrogen) and cloning into the EcoRI and XhoI
sites of pHybLex/Zeo. The 170- and 175-amino acid isoforms were also fused to the GAL4 DNA-binding domain, after cloning of the
corresponding cDNAs into the EcoRI and BamHI
sites of pAS2-1. The resulting fusion proteins were expressed into the
yeast reporter strains PJ69-4A (18) and Y190
(CLONTECH). Plasmid pASV3, used for construction of
the mouse embryo cDNA library (19), has already been described (20). For the interaction trap with LEXA-cvHsp, L40 yeast transformants were selected on plates lacking leucine, histidine, and lysine, supplemented with 300 µg of zeocin (Invitrogen) and 30 mM
3-aminotriazole (Sigma). The library inserts of clones positive in both
the growth and -galactosidase assays were recovered by PCR
amplification from yeast colonies and directly used for sequencing. All
nucleotide sequences were verified using an ABI PRISM 377 DNA sequencer
(Perkin-Elmer).
Antibody Production, Western Blotting, and
Immunoprecipitation--
The deduced amino acid sequence of
cvHsp was analyzed for highly antigenic regions using the
Jameson-Wolf antigenic index. The following synthetic peptide
QLPEDVDPTSVTSALR (amino acids 132-147) was synthesized (peptide
synthesizer model 431A, Applied Biosystems), purified and conjugated to
keyhole limpet hemocyanin using glutaraldehyde as the coupling agent.
Fourteen-week-old New Zealand rabbits were injected every 2 weeks with
peptide-carrier conjugate (150 µg/injection), and serum titers were
measured by enzyme-linked immunosorbent assay on unconjugated
peptide-coated plates. The immunoglobulins fraction from the cvHsp
immune serum, P672, were obtained by affinity chromatography on protein
A-Sepharose. For Western blotting, crude homogenates from normal human
heart were subjected to a 12.5% SDS-polyacrylamide gel electrophoresis under reducing conditions (2% -mercaptoethanol) and then
transferred to Biotrace polyvinylidene difluoride membranes (Gelman,
Champs-sur-Marne, France). Proteins were detected using purified P672
polyclonal antibody (500 ng/ml) revealed with a donkey anti-rabbit
antibody (NA934, Amersham Pharmacia Biotech), and an enhanced
chemiluminescence reagent (ECL Plus, Amersham Pharmacia Biotech). Other
antibodies used were monoclonal mouse anti-human -filamin (Chemicon
International), polyclonal rabbit anti-human alpha-B crystallin
(Serotec), and polyclonal goat anti-human Hsp27 (Santa Cruz
Biotechnology). Proteins complexes containing filamin were
immunoprecipitated from human heart homogenates (200 µg protein)
using anti-human -filamin antibodies and protein A-agarose (Santa
Cruz Biotechnology) according to the manufacturer's recommendations.
The immunoprecipitates were subjected to SDS-polyacrylamide gel
electrophoresis and revealed by the use of anti-cvHsp or
anti- B-crystallin antibodies.
Experimental Models of Cardiovascular and Metabolic
Pathologies--
The determination of the expression pattern of
cvHsp was performed in tissues from different experimental
models in rodents. All rats were obtained from IFFA Credo (St Germain
sur l'Arbresle, France) and were maintained and used according to the
National Institutes of Health guideline for the use of laboratory
animals. Right ventricular hypertrophy was obtained by a single
injection of monocrotaline (MCT) (60 mg/kg, subcutaneously) 3 weeks
before analysis. Left ventricular hypertrophy was obtained by chronic pressure overload induced by banding the abdominal aorta (aortic banding) above the renal artery of 5 week-old Wistar male rats. Aortic
stenosis was performed under pentobarbital anesthesia (30 mg/kg,
intraperitoneal) using a silver clip with a clearance of 0.1 mm.
Sham-operated animals underwent an identical procedure except that the
clip was not tied. The magnitude of the left ventricular hypertrophy
was assessed after 5 weeks by comparison of the left ventricular weight
to body weight ratio from operated/treated versus
sham-operated/treated animals. Other experimental models included
spontaneously hypertensive rats and their age-matched Wistar-Kyoto
controls, as well as Zucker obese and lean rats that were all 12 weeks
old. All animals were anesthetized with pentobarbital, and tissues were
withdrawn, rinsed in ice-cold RNase-free phosphate-buffered saline, and
frozen in liquid nitrogen for subsequent processing.
Statistical Analysis--
Values shown are mean ± S.E.
unless otherwise stated. Statistical analysis was made by using
analysis of variance, and a p < 0.05 was considered as
statistically significant.
 |
RESULTS |
Electronic Identification of cvHsp as a Selectively and Highly
Expressed Gene in Cardiac Libraries--
cvHsp was first
identified using the "selective expression" algorithm recently
reported by two of us (13) as an assembly highly "expressed" in
heart libraries. This computational approach was applied to large
abundance data bases (or reconstructed abundances from the dbEST and
Human Genome Science data bases). In this approach, selective
expression refers to a pattern of expression in one or a small number
of tissues in which there is markedly high or low expression against
the baseline of expression implicitly defined in the other tissues.
The assembly abundances were calculated as the number of "random"
ESTs that constituted a given assembly divided by the total number of
random ESTs generated from that given library. ESTs are counted as
random if they were initially selected as random and not as
subsequently "directed" sequencing, second walks, resequencings, the second EST of a 3'-5' pair, etc. Assembly expression was further divided into three levels of qualitative expression (high, medium, and
low) such that the total amount of RNA was the same (i.e. one-third) for each expression level. According to these criteria, cvHsp was identified as selectively and highly
"expressed" in heart. Indeed, cvHsp assembly represented
0.3% of the total RNA (not considering housekeeping genes; see Table
I). However, because of the variability
of sampling depth with different EST libraries, there can be a
substantial distortion of the reconstituted abundances that has to be
taken into account by the selective expression detection algorithm. To
correct for this limited sampling effect, we did not use the abundances
from Table I but first corrected the bias due to finite sampling (21,
22). The markedly elevated abundance in the heart libraries (mainly
adult but also fetal heart) of cvHsp assembly became
visually apparent (Fig. 1). According to
the criteria set for detecting selective expression of genes, significance probability of 5.5 × 10 7 was obtained
for the cvHsp abundance pattern as compared with a randomly
chosen pattern. Furthermore, the gap between the largest relative
abundance and the next-to-largest, which is an estimator of separation
of selective expression from baseline behavior and can only vary
between 0 and 1, was 0.78. Overall, the algorithm assesses the
cvHsp abundance pattern as a modestly strong selective expression pattern (see Ref. 13 for details). In addition to this
marked expression level in adult and fetal heart libraries, cvHsp was also found to be expressed in skeletal muscle and
to a lesser extent in breast, bone marrow stroma, and adipose
tissue.
View this table:
[in this window]
[in a new window]
|
Table I
cvHsp computational abundances in various libraries as reconstituted
from ESTs
cvHsp abundances as computed from EST proportions in
libraries are shown with the corresponding percentage of library total
abundance.
|
|

View larger version (5K):
[in this window]
[in a new window]
|
Fig. 1.
Computational expression pattern: selective
expression of cvHsp in heart libraries.
cvHsp abundances reconstituted from ESTs are plotted
versus library. Abundances (see Table I) have been scaled by
the maximum abundance for convenient emphasis. The marked elevation of
cvHsp in the heart library (lane 7) is
evident, as well as the clear separation from the levels in the other
libraries, which taken together represent a baseline level of
abundance. Libraries are as follows: Soares breast 2Nb HBst (lane
1), fetal heart (lane 2), Soares breast 3Nb HBst
(lane 3), Soares fetal lung NbHL19W (lane 4),
Soares senescent fibroblasts NbHsF (lane 5), Stratagene
human skeletal muscle cDNA (lane 6), Human heart
cDNA (YNakamura) (lane 7), Stratagene muscle 937209 (lane 8), synovial hypoxic fibroblasts (lane 9),
bone marrow stroma (lane 10), and human adipose tissue
(lane 11). (See Ref. 13 for details.)
|
|
Cloning of cvHsp--
The initial contig of cvHsp was
not assigned to any known protein, and most of the ESTs that composed
the initial cvHsp contig were accordingly unknown
(i.e. not homologous to known genes), probably because more
than 75% of the transcript consisted of the untranslated 5' and 3'
regions, regions known to have much less homology than the coding block
in a given family of genes. However, a few ESTs translated into an open
reading frame that shared significant identity with known members of
the smHsp family, i.e. Hsp27 and -crystallin. We gathered
124 ESTs by using BLAST (basic local alignment search tool) homology
searches, which resolved into a contiguous sequence of about 2.2 kb.
A further analysis of the sequence suggested the presence of three
different transcripts generated by alternative splicing (Fig.
2). One or two of the corresponding
cDNA clone variants from these three transcripts, obtained mainly
from cardiac or adipose tissue libraries, were requested and sequenced
to completion. Although the ATG codon in position 75 is in a poor Kozak
consensus environment (TGGATGA versus
ANNATGG) and no stop codon could be found upstream of the
start codon, 5'-rapid amplification of cDNA ends experiments
confirmed the obtained sequence and rendered unlikely the possibility
of the existence of another ATG codon upstream from that in position
75. In the three different types of transcripts, the 5' sequence was
identical in bp 1-273, a region named A, and in a segment of over 1000 bp, named region D. Isoform 1 has an additional sequence of 875 bp,
region E, just before the poly(A) tailing consensus signal AATAAA, thus
giving a total length of 2.15 kb (in the absence of the poly(A) tail),
in good agreement with the size of the major transcript determined by Northern blotting (2.3 kb; see below). The open reading frame of
isoform 1, from nucleotide 75 to 584, gave a deduced amino acid
sequence of 170 residues. Isoform 2 was represented in a second series
of sequenced clones: these have an additional 15-bp sequence in-frame
between segment A and D, named region C, which added 5 amino acids to
the 170-amino acid sequence. These clones missed the E region, thus
giving a transcript size of about 1.3 kb. In isoform 3, a region B of
542 bp was inserted between A and C: the corresponding sequenced clone
was of 1.8 kb. Interestingly, this B segment introduced a stop codon,
and the resulting deduced open reading frame (75-281) of isoform 3 was
of 68 residues (Fig. 2, panel 2). Segments A, B, and C have
the intronic (C/A)AG consensus sequence prior to the exon splicing
donor at the end of their 3' sequences in good agreement with the AB,
AC, AD, BC, and CD organization of the segments. Because the segments
are at least composed of one exon, a minimal organization of the gene
into five segments/exons could be envisaged (Fig. 2, panel
3). Full-length mouse and a partial rat cvHsp sequences were
identified and found to share 92-95% identity with the human sequence
at the amino acid level. The amino acid sequence comparison between
human and mouse cvHsp is presented (Fig. 2, panel 4).

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide sequence of cvHsp cDNA,
minimal organization of the cvHsp gene, and alignment
of human and mouse cvHsp protein sequences. The nucleotide
sequence presented in the left panel (panel 1) is
that of the mainly expressed cvHsp transcript (isoform 1, ADE segments), although the additional 15 bp and 5 deduced amino acids
present in the second and third transcripts only, corresponding to
segment C, are represented for clarity (position 274-288, in
boldface inside the rectangle). The 3 bp at the
end of segment D, at the junction with the E segment, are indicated
(boldface) at position 1272-1274. The sequence of segment B
with its interrupting stop codon (in boldface) is indicated
(panel 2). The open reading frames are of 170 amino acids
(bp 75-584) for transcript 1, 175 amino acids (bp 75-599) for
transcript 2, and 68 amino acids (bp 75-281) for transcript 3. The
existence of the three isoforms was confirmed after sequencing of the
corresponding clones. The minimal deduced organization of the
cvHsp gene is presented (panel 3) (for details,
see text). 1p36-p34 is the chromosome localization of the
cvHsp gene. Sequence comparison of human and mouse cvHsp is
presented (panel 4); these sequence shared 95% identity and
97% similarity.
|
|
Finally, seven of the components of cvHsp are NCBI ESTs with
known chromosome localization: these included ESTs with
GenBankTM accession numbers R49801, H44673, AA397963,
T19903, T20269, T20235, and T32631. The mapping location of these NCBI
ESTs were found to be deposited in the Unigene data base, and all were
in 1p36.23-p34.3 between markers D1S434 and
D1S507.
Expression Pattern of cvHsp mRNA in Normal Tissue, in Heart
Diseases, and in Obesity--
According to its "electronic" tissue
distribution, cvHsp is expected to be principally expressed
in cardiac tissue. We experimentally studied the expression pattern of
cvHsp gene using several approaches summarized in Fig.
3. First, the tissue distribution of
cvHsp was analyzed using a poly(A)+ RNA dot blot of 50 different tissues. The results show a high expression in adult and
fetal heart and in skeletal muscle; a fainter expression was evidenced
in the aorta. In contrast, cvHsp expression was virtually
undetectable in other organs tested, including 15 regions of the brain,
digestive tract, liver, lung, adrenal, thyroid, spleen, thymus, gonads, and placenta. Using a Northern blot analysis on 9 different tissues, a
main single transcript of 2.3 kb was observed in heart and skeletal muscle only (Fig. 3, left inset). Although cvHsp
mRNA could be readily detected after a 2-h exposure by Northern
blot with 10 µg of total RNA from human heart, which suggested a high
expression of the gene in this organ, a longer exposure revealed the
presence of ~1.2- and ~1.6-kb transcripts (not shown), which are
reminiscent of the sizes of transcript 2 and 3 respectively (Fig. 2,
panel 3).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Tissue distribution of cvHsp in human. A
prenormalized poly(A)+ RNA dot blot of 50 different tissues was
hybridized with a cvHsp probe and normalized with a
cyclophilin probe. Densitometry associated with hybridization was
analyzed using the Molecular Analyst software (Bio-Rad). Tissue sample
number correspondence was as follows: column 1, whole brain;
column 2, amygdala; column 3, caudate nuclei;
column 4, cerebellum; column 5, cerebral cortex;
column 6, frontal lobe; column 7, hippocampus;
column 8, medulla oblongata; column 9, occipital
lobe; column 10, putamen; column 11, substantia
nigra; column 12, temporal lobe; column 13, thalamus; column 14, subthalamic nuclei; column
15, spinal cord; column 16, heart; column
17, aorta; column 18, skeletal muscle; column
19, colon; column 20, bladder; column 21, uterus; column 22, prostate; column 23, stomach;
column 24, testis; column 25, ovary; column
26, pancreas; column 27, pituitary; column
28, adrenal; column 29, thyroid; column 30, salivary gland; column 31, mammary gland; column
32, kidney; column 33, liver; column 34, small intestine; column 35, spleen; column 36, thymus; column 37, peripheral leukocyte; column
38, lymph node; column 39, bone marrow; column
40, appendix; column 41, lung; column 42, trachea; column 43, placenta; column 44, fetal
brain; column 45, fetal heart; column 46, fetal
kidney; column 47, fetal liver; column 48, fetal
spleen; column 49, fetal thymus; column 50, fetal
lung. A main 2.3-kb transcript was observed with Northern blot analysis
of cvHsp (2 µg of poly(A)+, left panel). RT-PCR
on total RNA from normal heart and omental adipose tissue are displayed
in the right panel: lanes 2-7 are RT-PCR using
primers for cvHsp, and lane 7 is the control
without reverse transcriptase. Lane 1 is the amplification
of the 1-adrenergic receptor. RT-PCR was performed with
the following quantities of total RNA: 10 (lane 2), 20 (lane 3), 50 (lane 4), 100 (lane 5),
and 200 (lanes 1, 6, and 7) ng with 30 cycles of
amplification. Lane M is the 123-bp DNA ladder molecular
weight marker.
|
|
Although few ESTs were found to derive from adipose tissue libraries,
we have performed RT-PCRs on RNA from human abdominal subcutaneous
adipose tissue (Fig. 3, right inset). The mRNA levels of
cvHsp were semiquantitatively evaluated with amplifications performed with 10-200 ng of starting total RNA from adipose tissue and
heart. cvHsp could be readily amplified with 100 ng of total RNA in adipose tissue, and it appears, by comparison of signals obtained for 50 ng of RNA in heart and adipose tissue, to be expressed at lower levels in adipose tissue than in the heart.
cvHsp being mainly expressed in heart, but also in skeletal
muscle and adipose tissue, we hypothesized that, if regulated, cvHsp levels of expression may be altered in cardiovascular
pathologies and in metabolic disorders. Therefore, we determined the
expression levels of cvHsp mRNA in right and left
ventricles of hearts from rats with right ventricular hypertrophy
(treated with MCT) and left ventricular hypertrophy (spontaneously
hypertensive rats and aortic banding) and also in different tissues
from Zucker fatty rats (Fig. 4).

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 4.
cvHsp mRNA expression in rat models of
heart pathologies and in insulin-sensitive tissues in genetically obese
Zucker rats. Northern blot analyses of cvHsp expression
using 2 µg of poly(A)+ RNA from heart left (LV) and right
(RV) ventricles from spontaneously hypertensive rats
(SHR) and their Wistar-Kyoto (WKY) controls and
in monocrotaline-treated rats (MCT) and their sham control
(SHA), chronic pressure overload in rats resulting from
aortic banding (Ao. Ba.) and their sham control
(SHA) (A) and in heart, skeletal muscle (from
hind limb), interscapular brown adipose tissue (BAT), and
epididymal white adipose tissue (WAT) from obese Zucker rats
(fa/fa) and their lean (Fa/ ) controls (B). Densitometric
values obtained after ubiquitin hybridization were used to normalize
cvHsp expression and are presented in arbitrary units. Each
sample consisted of a pool of RNA from three different tissues. A
representative experiment is presented. Experiments were reproduced two
or three times. The rat cvHsp cDNA probe was generated
using the human primers described under "Experimental Procedures,"
sequenced, and shown to share 88% identity with the human nucleotide
sequence over 280 bp. The probe hybridized to a single 2.0-kb
transcript.
|
|
cvHsp mRNA expression level in heart was not changed in
12-week-old spontaneously hypertensive rats compared with age matched Wistar-Kyoto control rats. When using a model of pressure overload with
aortic banding, in which the ratio of left ventricular weight to body
weight increased from 1.97 ± 0.03 in sham-operated rats (n = 8) to 2.59 ± 0.07 in rats subjected to
aortic stenosis for 8 weeks (n = 17, p < 0.001), there was a 2-fold decrease in cvHsp mRNA
expression in both ventricles. In contrast, in MCT-treated hearts, the
expression level of cvHsp was increased. In these rats, MCT
induced a pulmonary hypertension, leading to an increase in the right
ventricle mass (from 238 ± 17 mg in control rats receiving
vehicle (n = 8) to 381 ± 39 mg in rats treated
with MCT (n = 10, p < 0.001), whereas
left ventricle mass remained unchanged (860 ± 18 and 841 ± 34 mg in control and MCT-treated rats, respectively)). After treatment
by MCT, cvHsp mRNA expression level was increased
2.5-fold, in both the right and left ventricles, irrespectively of the
site of hypertrophy (Fig. 4). It should be noticed that blots were
normalized with ubiquitin, which is considered as a member of the smHsp
family (23). Ubiquitin levels could possibly be modulated in the hearts
from the different models of cardiac pathologies, thus rendering
specious interpretation of the results. However, in MCT rats, a similar
increase in cvHsp mRNA levels was obtained following
normalization with glyceraldehyde-3-phosphate dehydrogenase (not
shown), and, in right ventricle from aortic banded rats as compared
with sham operated controls, ubiquitin levels are comparable, whereas
cvHsp is clearly down-regulated (Fig. 4A).
Finally, the expression patterns of cvHsp mRNA were
investigated in heart, skeletal muscle, and white and brown adipose
tissues in a model of insulin-resistance associated with obesity, the Zucker fatty rat. Although there was no changes in cvHsp
expression in hearts from obese rats, there was a 2-fold increase in
cvHsp mRNA steady state levels in skeletal muscle (hind
limb) (Fig. 4). Likewise, cvHsp expression in interscapular
brown fat and epididymal white fat was increased 4-5 times in obese
rats compared with their lean controls. Similar results were obtained
after a 28 S ribosomal RNA normalization (not shown).
Characterization of cvHsp as a Novel Small Heat Shock
Protein--
To determine the apparent molecular weight of cvHsp, we
performed Western blot analyses on heart homogenates from normal human heart (Fig. 5). Antibodies raised against
human B-crystallin and Hsp27 were used as controls and allowed the
detection of a band at 20 and 27 kDa, respectively, as expected. The
anti-cvHsp revealed a major band at 25 kDa and a less abundant band at
23 kDa, which were absent in the control preimmune antiserum. The two
cvHsp bands could not be detected when the antibody was immunodepleted with the peptide that served for immunization. Because the identity of
the two bands is not fully understood at the present time, and to avoid
confusion with the rodent ortholog of human Hsp27, which is often
called Hsp25, we suggest that this novel smHsp not be named after its
molecular weight, as generally done for smHsps (1, 24). Rather, we
propose that this novel smHsp be named cvHsp after its high expression
in cardiovascular and insulin-sensitive tissues.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 5.
Multialignment of small heat shock proteins,
their sequence comparison, and Western blots analyses of cvHsp, Hsp27,
and B-crystallin. Multialignment of
-crystallin A chain (CraA) (GenBankTM
accession number P02489), -crystallin B chain (CraB)
(P02511), Hsp20 (B53814), Hsp -2 or MKBP (Hsp beta-2 and
hspB2) (U75898), Hsp27 (P04792), Hsp27-like
(Hspl27) (U15590) and cvHsp (transcript 2 of 175 amino
acids) is displayed in the left panel. Consensus (six
identical out of seven) and conservative mutations are shown in
boldface. The sequence characteristics of the small Hsp
family are indicated by boxed arrows on the majority line.
Length of the proteins are indicated. Homologies and identities between
the small Hsps are presented in the two-entry table (determined using
Bestfit algorithm). Western blot analyses (top right panel)
were as follows: homogenate from human normal heart (10 µg of
protein) was subjected to SDS-polyacrylamide gel electrophoresis and
blotted with antibodies against cvHsp, Hsp27, or B-crystallin.
Molecular weight markers and molecular size of the bands are indicated
at the left and right of each image,
respectively. cvHsp blots were done either in the presence (+) or
absence ( ) of the peptide that served for immunization. Preimmune
serum was used as control.
|
|
The comparison of cvHsp amino acid sequence with known proteins
revealed the highest level of homology with the members of the smHsp
family. The alignment of cvHsp amino acid sequence with that of
A-crystallin, B-crystallin, Hsp20, Hsp -2 (or MKBP), Hsp-like
27, and Hsp27 is presented in Fig. 5. All seven smHsp shown in Fig. 5
are of similar length, between 160 and 241 amino acids. Although
divergent in their N-terminal region, this family is characterized
structurally by the presence of a conserved C-terminal domain of about
80-100 residues (3). Motif analysis using two-dimensional visualization tools (25) suggested this C-terminal region was of about
80 amino acids (precisely 80 amino acids in the case of cvHsp), leaving
further downstream a divergent region of 1-32 residues (13 for cvHsp),
depending on the smHsp considered (not shown). Overall, cvHsp shared
24-30% identity and 45-54% homology with the other members of the
smHsp family. These were higher when solely the C-terminal smHsp
signature was taken into account: up to 36 and 58% of identity and
homology, respectively. Finally, scanning of cvHsp to ProSite motifs
identifies the heat shock Hsp20 protein family motif (PS00791) in the
region of residues 85-158 of cvHsp. Altogether, these results clearly
assign cvHsp to the small heat shock protein family.
cvHsp Interacts with -Filamin--
Because Hsps are mainly
chaperones known to associate with proteins, an interaction trap
designed to identify proteins that could interact with cvHsp has been
carried out in yeast. The complete open reading frame of the 170-amino
acid isoform of cvHsp has been cloned into the yeast expression vector
pHybLex/Zeo, which allows the expression of proteins fused to the LEXA
DNA-binding domain. The resulting fusion protein, thereafter referred
to as LEXA-cvHsp, has been used as a bait in a two-hybrid screening carried out in the L40 yeast reporter strain, after transformation with
a mouse embryo cDNA library constructed into the pASV3 plasmid, which contains the transcriptional activation domain of the VP16 viral
protein (20). Given the 95% identity and 97% similarity between the
human and mouse cvHsp protein sequences, the two-hybrid experiments
were performed with an already reported well characterized mouse embryo
library (19, 20). Screening of roughly 15 million independent yeast
transformants on plates lacking histidine and supplemented with 30 mM 3-aminotriazole led to the selection of 840 clones.
Among the 155 clones sequenced, 19 library plasmids contained inserts
corresponding to the mouse ortholog of human actin-binding protein 280 or -filamin cloned by Gorlin et al. (14) (the mouse
filamins are not fully cloned). Indeed, these sequences were assembled
into three consensus sequences of 446, 598, and 699 bp. These
nucleotide sequences were compared using the FrameSearch tool (GCG) to
the protein sequence of human -filamin (14), -filamin (26, 27),
and -filamin (28), the three known filamins. Average identities were
90, 70, and 75% with -, -, and -filamin, respectively. These
data strongly suggest that isolated clones from mouse were orthologs of
the human -filamin. The obtained mouse sequences covered amino acids
2181-2598 of human -filamin. The shortest mouse filamin clone
isolated in the two-hybrid experiments, hip284, contained a sequence
homologous to amino acids 2424-2598 of human -filamin. To further
characterize cvHsp interaction with -filamin, we investigated 1)
which part of cvHsp could be involved in the interaction with
-filamin, and 2) whether this interaction could be observed in the
human heart.
We thus generated deletion mutants of cvHsp by RT-PCR and
used them in an interacting trap with hip284. Three truncated forms of
cvHsp were generated and included amino acids including intervals 41-170, 56-170, and 119-170. The full-length clone of
cvHsp and the two truncated clones containing segments of
amino acids 41-170 and 56-170 were positive in both the growth and
-galactosidase assays of this two-hybrid experiment (Table
II). In contrast, the clone containing
amino acids 119-170 did not interact with -filamin (hip284),
suggesting that amino acids 56-119 of cvHsp were important for the
interaction with -filamin.
View this table:
[in this window]
[in a new window]
|
Table II
Mapping of cvHsp domains that interacted with the mouse ortholog of
human -filamin (ABP-280)
cvHsp deletion mutants were generated by RT-PCR and assayed for their
interaction with the shortest clone found in two hybrid experiments,
hip284, which corresponded to residues 2424-2598 of -filamin.
Constructs positive in both the growth and -galactosidase assays are
indicated (+).
|
|
Finally, to confirm whether the interaction between cvHsp and
-filamin identified using the yeast two-hybrid study can take place
in normal human heart, we tested the existence of cvHsp/ -filamin interaction with co-immunoprecipitation experiments in human heart homogenates. In these experiments, immunodetection of cvHsp was performed after immunoprecipitation of human heart homogenates with
monoclonal antibodies raised against human -filamin (Fig. 6). The coprecipitation of cvHsp, but not
of B-crystallin, with human -filamin, confirmed the interaction
between these proteins. Furthermore, these experiments show that the
interaction between cvHsp and -filamin indeed occurs in the human
heart.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 6.
Co-immunoprecipitation of
-filamin with cvHsp. Homogenate from human
normal heart (200 µg of protein) was immunoprecipitated (+) with
monoclonal antibody raised against -filamin, subjected to
SDS-polyacrylamide gel electrophoresis, and blotted with specific
antibodies raised against cvHsp or B-crystallin.
Nonimmunoprecipitated ( ) heart homogenate was used as positive
controls. Molecular weight markers are indicated.
|
|
 |
DISCUSSION |
The results of the present study show that novel genes with a
tissue-selective pattern of expression can be identified by computer-based alignment of ESTs combined with a selective expression algorithm applied to abundance patterns. With this approach, we identified and cloned a novel low molecular weight (25,000) heat shock
protein, called cvHsp, according to its abundant expression in
cardiovascular tissue. The present study provides some insight into the
mechanism of action of cvHsp by providing evidence of its interaction
with -filamin.
Searches in EST data bases are increasingly being used to mine for
cDNA sequences from an homolog gene either in the same, i.e. paralogs (e.g. see Ref. 29) or in other
species, i.e. orthologs (e.g. see Ref. 30). In
effect, there are now over 2.4 million ESTs (dbEST release 052199) in
the publicly available data bases, not taking into account data
generated by sequencing companies contracted by pharmaceutical
industries (31). Altogether, these ESTs are thought to cover the
majority of the 65,000-80,000 genes in the human genome. Gene
discovery using EST data bases is most often performed by homology
searches using the BLAST or FASTA algorithms and their variants as
nucleotide or protein queries in data bases of nucleotides, proteins,
or nucleotides translated in the six reading frames (for more details,
see Ref. 10). More recently, strategies based on text searching in
sequence annotations were used to find novel genes, as shown with the
discovery of a novel calcium channel type (11). Similarly, primary
selection of ESTs from prostate libraries using keywords and further
contig constructions lead to the identification of three
prostate-specific cDNA contigs for which no further information was
disclosed (12). We have augmented such search strategies by including
expression information as well. This includes both patterns of
expression (e.g. selective expression) and levels of
expression in particular libraries. The selective expression pattern
detection algorithm we have used (13) enabled us to determine that a
particular assembly was selectively and highly abundant in heart
libraries compared with that from other tissues. This has turned out to be potent combination to find new highly expressed genes with tissue-selective patterns of expression.
The computational expression pattern revealed that cvHsp was
most abundant in heart libraries, with a level of expression calculated
as high (Table I, Fig. 1). This high and selective expression in heart
was experimentally confirmed by RNA dot-blot, Northern blot, or RT-PCR,
as was the lesser expression in skeletal muscle, adipose tissue, and aorta.
It is well established that Hsps are overexpressed in pathologic
situations in which a protection of the heart is evidenced and that a
heat shock response is associated with enhanced postischemic recovery
(32, 33). Therefore, we measured cvHsp mRNA expression in different pathologies in which the heart muscle modifies its contractile and electrophysiological activities, its mass, and its
structure to adapt to a chronic stress (34, 35). cvHsp expression was unchanged in the hypertrophied heart of the spontaneous hypertensive rats. By contrast, cvHsp mRNA expression
was about 2-fold decreased in both ventricles from hearts of rats with
chronic pressure overload. These results suggest that no relationship can be established between developed heart hypertrophy and
cvHsp expression. In addition, it appears that the
overexpression of cvHsp observed in rats treated with MCT is
not linked to right heart hypertrophy because it was observed in both
ventricles. A similar increased in the two ventricles was observed in
MCT-treated rats for Hsp72 (35). Altogether, these results
suggest that cvHsp may not be directly involved in already installed
cardiac pathologies. Likewise, no modification of cvHsp
expression was noted in hearts from obese Zucker rats as reported for
Hsp72 (36). On the other hand, our results show that
cvHsp mRNA is overexpressed in the other
insulin-sensitive tissues in obese Zucker rats. This suggests that
cvHsp may be associated with obesity and related metabolic
disorders. Interestingly, although a reduction of Hsp70 has
been shown in diabetes in brown adipose tissue (37), and upon
differentiation in the 3T3-L1 preadipocyte line (38), there is no
report of smHsp expression profile or regulation in adipose tissue in
obesity. The selective expression of a gene in heart, skeletal muscle,
and white and brown adipose tissue is not unique to cvHsp,
as a similar expression pattern has been reported for other proteins
involved in nutritional disorders, such as the insulin-responsive
glucose transporter GLUT4 (39). Because such proteins are often
regulated by insulin, catecholamines, or steroids, we could speculate
that similar regulation might alter cvHsp expression. Although this remains to be tested for cvHsp, altered
expression of Hsp genes has been reported following treatment by
insulin for Hsp72 (40), noradrenaline for Hsp27
and B-crystallin (41), and estrogen for Hsp27
(42).
cvHsp was shown to share an average of 26 and 49% identity and
homology, respectively, with the six other known members of the smHsp
family. Although these are lower than homologies between A-crystallin, B-crystallin, Hsp20, Hsp27, and Hsp -2, these are
similar to that found for Hspl27 (Fig. 5). Phylogenically, cvHsp,
Hsp-like 27, and Hsp -2 were closer to each other than to the other
members of the smHsp family. In the conserved C-terminal domain of
about 80 amino acid residues that characterizes the smHsp superfamily
( -crystallin domain), cvHsp had a higher percentage of identity (up
to 36%) and homology (58%) with the other smHsp. Importantly, this
so-called -crystallin domain can be found in all known smHsp,
including cvHsp, which we describe here, but has never been seen in any
other protein.
Western blot analyses in human heart homogenate revealed the presence
of two specific bands at 23 and 25 kDa for cvHsp. The major
posttranscriptional modifications of the smHsp proteins are
phosphorylations notably by cyclic AMP-dependent protein
kinase and cyclic GMP-dependent protein kinase,
mitogen-activated protein kinase-activated protein kinase-2, protein
kinase C, and p44/42 mitogen-activated protein kinase (e.g.
see Ref. 43 and references therein). Putative consensus phosphorylation
functional motifs were found in the cvHsp protein (175-amino acid
isoform) sequence: five protein kinase C phosphorylation sites (Ser-2,
Thr-8, Thr-71, Thr-153, and Thr-168) and two casein kinase II
phosphorylation sites (Thr-82 and Ser-97). However, it remains to be
established whether these two 23- and 25-kDa bands corresponded to the
170- and 175-amino acid residue isoforms and/or to different
phosphorylation states of cvHsp.
Structure-function studies demonstrated that the C terminus
-crystallin domain of small Hsps is responsible for chaperone function, whereas the N terminus was involved in multimerization of the
proteins (44). It has been reported that A- and B-crystallin could be truncated, leaving part of the N-terminal region without the
-crystallin domain (reviewed in Ref. 3). Interestingly, this could
also be the case for cvHsp, as transcript 3 encoded a
putative protein of 68 amino acids forming solely the N-terminal region
of the protein with complete exclusion of the C-terminal -crystallin
domain, suggesting that cDNA transcript 3 might encode a
multimerization regulatory component. Finally, the length of 170 or 175 amino acid residues compares well with the size of the prototypic
member of smHsp, A-crystallin (173 residues) and with that of the
other members (160-241 residues). Altogether, these data clearly
assigned cvHsp to the superfamily of smHsp.
smHsps are chaperones that interact with and stabilize proteins that
are damaged during biological stresses. These are mainly, but not
solely, cytoskeleton proteins. B-crystallin interacts with actin,
desmin, and vimentin in the heart (4, 5); Hsp27 interacts with actin
and platelet factor XIII (6, 7). No data are available for Hsp20 or
Hspl27. More recently Hsp -2, also called MKBP, was shown to bind and
activate myotonic dystrophy protein kinase (8). We report here that
cvHsp binds both in the two-hybrid and co-immunoprecipitation
experiments the cytoskeleton protein -filamin (or actin-binding
protein 280) and provide evidence that it occurs in the heart.
Noticeably, the tissue distribution of -filamin,
characterized by highest expression in heart and skeletal muscle (26),
is relevant to that of cvHsp. The N-terminal region of human
-filamin contains the actin-binding domain, followed by a
semiflexible rod-like domain consisting of 24 homologous repeats, each
of about 96 amino acids, with a total length of 2647 (14). Filamins
appear to function as promoters of actin polymerization (45) and to
connect cell membrane proteins to the cytoskeleton. Among these
proteins are glycoprotein Ib (46), which, when complexed in the
GPIa-Ib-V-IX heterotetramers, constitutes the major transmembrane
receptor for von Willebrand factor. In addition to GpIb , -filamin
associates with other membrane proteins, including IgG receptor Fc RI
(47), the 2-integrin CD18 subunit (48), presenilin-1 (49), tissue
factor (50), the calcium-dependent serine proteinase furin
(51), acetylcholine receptors (52), thyroid-stimulating hormone
receptor (53), the cytoplasmic mitogen-activated protein kinase-4
(MKK-4) (54), and, as shown in the present study, the small stress
protein cvHsp. Among the proteins known to interact with filamins, only
the domains for GPIb , furin, presenilin-1, and MKK-4 have been
identified. These are for GPIb repeats 17-19 (54, 55), for furin
repeats 13-14 (residues 1490-1607) (51), for presenilin-1 repeats
22-24 (49), and for MKK-4 repeats 21-23 (residues 2282-2454) (55).
We report here that the filamin domain for cvHsp binding covers repeats 23-24 (residues 2424-2598), including the C-terminal tail, a domain implicated in self dimerization (14), suggesting that cvHsp could be
involved in the stabilization of dimerized filamin. Following back to
the phosphorylation purpose, the proximity of MKK-4 and cvHsp on
filamin suggests additional working hypotheses. Within cvHsp, we showed
that a domain of 64 amino acids, at least corresponding to amino acids
56-119, was important for its specific interaction with filamin. This
domain encompasses a majority of amino acids present in the
-crystallin domain, in line with the known role for this domain in
interactions with chaperoned proteins (44).
Finally, the human cvHsp gene has been mapped to chromosome
1p36.23-p34.3 between markers D1S434 and D1S507,
a region representing 4 cM (~4 Mbp). It is noteworthy that several
genetic diseases with a pathophysiology compatible with the expression
pattern and the putative role of cvHsp have been mapped within this
interval, in particular, a DNA region in 1p36 between D1S243
and D1S2660 has been associated with cardiomyopathy (56).
Importantly, a missense mutation in B-crystallin was shown to cause
a desmin-related myopathy, indicating that alteration in a smHsp can be
responsible for a cytoskeleton-linked inherited disorder (57). This
suggests that cvHsp could be a good candidate for genetic
disorders mapped to 1p36-34 and characterized by cardiomyopathy or
myopathy for which the defective genes are still unknown.
In conclusion, we have identified a novel smHsp primary using a novel
bioinformatic strategy based on selective expression algorithms. This
25-kDa smHsp, called cvHsp, was preferentially expressed in
cardiovascular and insulin-sensitive tissues. Modulation of
cvHsp expression in obesity suggests that cvHsp
may be associated with obesity and related metabolic disorders. In
addition, the gene localization of cvHsp in 1p34-36
comprises that for several dystrophies and myopathies, including
cardiomyopathy, suggesting that cvHsp could be a candidate
gene for these diseases. Our results further demonstrate that cvHsp
interacted with -filamin and thus could act as a chaperone protein.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Christian Carpéné
(INSERM U. 317, Toulouse, France) for kindly providing human adipose
tissue, Dr. Xiohua Gong (The Scripps Research Institute, La Jolla, CA)
for the gift of RNA from rat lenses, Stéphane Dréano (CNRS
UPR 041, Rennes, France) for sequencing on the ABI PRISM 377 DNA
sequencer, and Laurence Tourtelier and Marie-Paule Laville for skillful
technical assistance. Two-hybrid experiments were performed by Dr.
Bertrand Le Douarin in the laboratory facilities of Prof. Francis
Galibert (CNRS UPR 041, Rennes, France).
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article is dedicated to the memory of Dr. Bertrand Le Douarin.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF155908 (human), AF155909 (mouse), and AF155910 (rat).
§
To whom correspondence should be addressed. Tel.: 33-299-280-04-40;
Fax: 33-299-280-04-44; E-mail: Stephane_Krief@sbphrd.com.
¶
Recipient of a SmithKline Beecham/CNRS postdoctoral fellowship.
Deceased.
 |
ABBREVIATIONS |
The abbreviations used are:
Hsp, heat shock
protein;
smHsp, small stress protein;
EST, expressed sequence tag;
kb, kilobase(s);
bp, base pair(s);
RT, reverse transcription;
PCR, polymerase chain reaction;
MCT, monocrotaline;
MKK, mitogen-activated
protein kinase;
MKBP, myotonic dystrophy protein
kinase binding protein.
 |
REFERENCES |
| 1.
|
Benjamin, I. J.,
and McMillan, D. R.
(1998)
Circ. Res.
83,
117-132[Abstract/Free Full Text]
|
| 2.
|
Morimoto, R. I.,
and Santoro, M. G.
(1998)
Nat. Biotechnol.
16,
833-838[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Groenen, P. J. T. A.,
Merck, K. B.,
de Jong, W. W.,
and Bloemendal, H.
(1994)
Eur. J. Biochem.
225,
1-19[Medline]
[Order article via Infotrieve]
|
| 4.
|
Bennardini, F.,
Wrzosek, A.,
and Chiesi, M.
(1992)
Circ. Res.
71,
288-294[Abstract/Free Full Text]
|
| 5.
|
Nicholl, I. D.,
and Quinlan, R. A.
(1994)
EMBO J.
13,
945-953[Medline]
[Order article via Infotrieve]
|
| 6.
|
Miron, T.,
Vancompernolle, K.,
Vandekerckhove, J.,
Wilchek, M.,
and Geiger, B.
(1991)
J. Biol. Chem.
114,
255-261
|
| 7.
|
Zhu, Y.,
O'Neill, S.,
Saklatvala, J.,
Tassi, L.,
and Mendelsohn, M. E.
(1994)
Blood
84,
3715-3723[Abstract/Free Full Text]
|
| 8.
|
Suzuki, A.,
Sugiyama, Y.,
Hayashi, Y.,
Nyu-i, N.,
Yoshida, M.,
Nonaka, I.,
Ishiura, S.,
Arahata, K.,
and Ohno, S.
(1998)
J. Cell Biol.
140,
1113-1124[Abstract/Free Full Text]
|
| 9.
|
Sikela, J. M.,
and Auffray, C.
(1993)
Nat. Genet.
3,
189-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Andrade, M. A.,
and Sander, C.
(1997)
Curr. Opin. Biotechnol.
8,
675-683[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Perez-Reyes, E.,
Cribbs, L. L.,
Daud, A.,
Lacerda, A. E.,
Barclay, J.,
Williamson, M. P.,
Fox, M.,
Rees, M.,
and Lee, J. H.
(1998)
Nature
391,
896-900[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Vasmatzis, G.,
Essand, M.,
Brinkmann, U.,
Lee, B.,
and Pastan, I.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
300-304[Abstract/Free Full Text]
|
| 13.
|
Greller, L. D.,
and Tobin, F. L.
(1999)
Genome Res.
9,
282-296[Abstract/Free Full Text]
|
| 14.
|
Gorlin, J. B.,
Yamin, R.,
Egan, S.,
Stewart, M.,
Stossel, T. P.,
Kwiatkowski, D. J.,
and Hartwig, J. H.
(1990)
J. Cell Biol.
111,
1089-1105[Abstract/Free Full Text]
|
| 15.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 16.
|
Krief, S.,
Fève, B.,
Baude, B.,
Zilberfarb, V.,
Strosberg, A. D.,
Pairault, J.,
and Emorine, L. J.
(1994)
J. Biol. Chem.
269,
6664-6670[Abstract/Free Full Text]
|
| 17.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 18.
|
James, P.,
Halladay, J.,
and Craig, E. A.
(1996)
Genomics
144,
1425-1436
|
| 19.
|
vom-Baur, E.,
Zechel, C.,
Heery, D.,
Heine, M. J.,
Garnier, J. M.,
Vivat, V.,
Le Douarin, B.,
Gronemeyer, H.,
Chambon, P.,
and Losson, R.
(1996)
EMBO J.
15,
110-124[Medline]
[Order article via Infotrieve]
|
| 20.
|
Le Douarin, B.,
Pierrat, B.,
vom Baur, E.,
Chambon, P.,
and Losson, R.
(1995)
Nucleic Acids Res.
23,
876-878[Free Full Text]
|
| 21.
|
Good, I. J.
(1953)
Biometrica
40,
237-264[CrossRef]
|
| 22.
|
Good, I. J.,
and Toulmin, G. H.
(1956)
Biometrica
43,
45-63[CrossRef]
|
| 23.
|
Mayer, R. J.,
Arnold, J.,
Laszlo, L.,
Landon, M.,
and Lowe, J.
(1991)
Biochim. Biophys. Acta
1089,
141-157[Medline]
[Order article via Infotrieve]
|
| 24.
|
Lindquist, S.,
and Craig, E. A.
(1988)
Annu. Rev. Genet.
22,
631-677[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Callebaut, I.,
Labesse, G.,
Durand, P.,
Poupon, A.,
Canard, L.,
Chomilier, J.,
Henrissat, B.,
and Mornon, J.-P.
(1997)
Cell. Mol. Life. Sci.
53,
621-645[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Takafuta, T.,
Wu, G.,
Murphy, G. F.,
and Shapiro, S. S.
(1998)
J. Biol. Chem.
273,
17531-17538[Abstract/Free Full Text]
|
| 27.
|
Xu, W. f.,
Xie, Z.,
Chung, D. W.,
and Davie, E. W.
(1998)
Blood
92,
1268-1276[Abstract/Free Full Text]
|
| 28.
|
Xie,
Zw,
Xu,
Wf,
Davie, E. W.,
and Chung, D. W.
(1998)
Biochem. Biophys. Res. Commun.
251,
914-919[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Masuhara, M.,
Sakamoto, H.,
Matsumoto, A.,
Suzuki, R.,
Yasukawa, H.,
Mitsui, K.,
Wakioka, T.,
Tanimura, S.,
Sasaki, A.,
Misawa, H.,
Yokouchi, M.,
Ohtsubo, M.,
and Yoshimura, A.
(1998)
Biochem. Biophys. Res. Commun.
239,
439-446
|
| 30.
|
Zeng, Z.,
Kyaw, H.,
Gakenheimer, K. R.,
Augustus, M.,
Fan, P.,
Zhang, X.,
Su, K.,
Carter, K. C.,
and Li, Y.
(1997)
Biochem. Biophys. Res. Commun.
236,
389-395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Zweiger, G.,
and Scott, R. W.
(1997)
Curr. Opin. Biotechnol.
8,
684-687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Currie, R. W.,
Karmazyn, M.,
Kloc, M.,
and Mailer, K.
(1988)
Circ. Res.
63,
543-549[Abstract/Free Full Text]
|
| 33.
|
Marber, M. S.,
Latchman, D. S.,
Walker, J. M.,
and Yellon, D. M.
(1993)
Circulation
88,
1264-1272[Abstract/Free Full Text]
|
| 34.
|
Swynghedauw, B.
(1992)
Basic. Res. Cardiol.
87 Suppl 2,
1-10[CrossRef]
|
| 35.
|
Ferrari, R.,
Bongrazio, M.,
Cargnoni, A.,
Comini, L.,
Pasini, E.,
Gaia, G.,
and Visioli, O.
(1996)
J. Mol. Cell. Cardiol.
28,
2383-2395[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Vincent, H. K.,
Powers, S. K.,
Stewart, D. J.,
Shanely, R. A.,
Demirel, H.,
and Naito, H.
(1999)
Int. J. Obes. Relat. Metab. Disord.
23,
67-74[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Matz, J. M.,
LaVoi, K. P.,
Epstein, P. N.,
and Blake, M. J.
(1996)
Am. J. Physiol.
270,
R525-R532[Abstract/Free Full Text]
|
| 38.
|
Liu, A. Y.,
Choi, H. S.,
and Bae-Lee, M. S.
(1990)
Biochem. Biophys. Res. Commun.
172,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Bell, G. I.,
Kayano, T.,
Buse, J. B.,
Burant, C. F.,
Takeda, J.,
Lin, D.,
Fukumoto, H.,
and Seino, S.
(1990)
Diabetes Care
13,
198-208[Abstract]
|
| 40.
|
Hong-Brown, L. Q.,
and Brown, C. R.
(1994)
Glia
12,
211-218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Kato, K.,
Ito, H.,
Hasegawa, K.,
Inaguma, Y.,
Kozawa, O.,
and Asano, T.
(1996)
J. Neurochem.
66,
946-950[Medline]
[Order article via Infotrieve]
|
| 42.
|
Cooper, L. F.,
and Uoshima, K.
(1994)
J. Biol. Chem.
269,
7869-7873[Abstract/Free Full Text]
|
| 43.
|
Kato, K.,
Ito, H.,
Inaguma, Y.,
Iwamoto, I.,
and Saga, S.
(1998)
J. Biol. Chem.
273,
28346-28354[Abstract/Free Full Text]
|
| 44.
|
Leroux, M. R.,
Melki, R.,
Gordon, B.,
Batelier, G.,
and Candido, E. P. M.
(1997)
J. Biol. Chem.
272,
24646-24656[Abstract/Free Full Text]
|
| 45.
|
Weihing, R. R.
(1985)
Can. J. Biochem. Cell Biol.
63,
397-413[Medline]
[Order article via Infotrieve]
|
| 46.
|
Andrews, R. K.,
and Fox, J. E. B.
(1991)
J. Biol. Chem.
266,
7144-7147[Abstract/Free Full Text]
|
| 47.
|
Ohta, Y.,
Stossel, T. P.,
and Hartwig, J. H.
(1991)
Cell
67,
275-282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Sharma, C. P.,
Ezzell, R. M.,
and Arnaout, M. A.
(1995)
J. Immunol.
154,
3461-3470[Abstract]
|
| 49.
|
Zhang, X.,
Han, S.,
McKeel, D. W.,
Goate, A.,
and Wu, J. Y.
(1998)
J. Neurosci.
18,
914-922[Abstract/Free Full Text]
|
| 50.
|
Ott, I.,
Fischer, E. G.,
Miyagi, Y.,
Mueller, B. M.,
and Ruf, W.
(1998)
J. Cell Biol.
140,
1241-1253[Abstract/Free Full Text]
|
| 51.
|
Liu, G.,
Thomas, L.,
Warren, R. A.,
Enns, C. A.,
Cunningham, C. C.,
Hartwig, J. H.,
and Thomas, G.
(1997)
J. Cell Biol.
139,
1719-1733[Abstract/Free Full Text]
|
| 52.
|
Shadiack, A. M.,
and Nitkin, R. M.
(1991)
J. Neurobiol.
22,
617-628[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Leedman, P. J.,
FaulknerJones, B.,
Cram, D. S.,
Harrison, P. J.,
West, J.,
O'Brien, E.,
Simpson, R.,
Coppel, R. L.,
and Harrison, L. C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
5994-5998[Abstract/Free Full Text]
|
| 54.
|
Marti, A.,
Luo, Z.,
Cunningham, C.,
Ohta, Y.,
Hartwig, J.,
Stossel, T. P.,
Kyriakis, J. M.,
and Avruch, J.
(1997)
J. Biol. Chem.
272,
2620-2628[Abstract/Free Full Text]
|
| 55.
|
Meyer, S. C.,
Zuerbig, S.,
Cunningham, C. C.,
Hartwig, J. H.,
Bissell, T.,
Gardner, K.,
and Fox, J. E. B.
(1998)
J. Biol. Chem.
272,
2914-2919[Abstract/Free Full Text]
|
| 56.
|
Wu, Y. Q.,
Heilstedt, H. A.,
Bedell, J. A.,
May, K. M.,
Starkey, D. E.,
McPherson, J. D.,
Shapira, S. K.,
and Shaffer, L. G.
(1999)
Hum. Mol. Genet.
8,
313-321[Abstract/Free Full Text]
|
| 57.
|
Vicart, P.,
Caron, A.,
Guicheney, P.,
Li, Z.,
Prevost, M. C.,
Faure, A.,
Chateau, D.,
Chapon, F.,
Tome, F.,
Paulin, D.,
and Fardeau, M.
(1998)
Nat. Genet.
20,
92-95[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. A. Griffin, H. Feng, M. Tewari, P. Acosta, M. Kawana, H. L. Sweeney, and D. E. Discher
{gamma}-Sarcoglycan deficiency increases cell contractility, apoptosis and MAPK pathway activation but does not affect adhesion
J. Cell Sci.,
April 1, 2005;
118(7):
1405 - 1416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. Morrison, R. J. Whittaker, R. E. Klepper, E. F. Wawrousek, and C. C. Glembotski
Roles for {alpha}B-crystallin and HSPB2 in protecting the myocardium from ischemia-reperfusion-induced damage in a KO mouse model
Am J Physiol Heart Circ Physiol,
March 1, 2004;
286(3):
H847 - H855.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Sun, J.-M. Fontaine, J. S. Rest, E. A. Shelden, M. J. Welsh, and R. Benndorf
Interaction of Human HSP22 (HSPB8) with Other Small Heat Shock Proteins
J. Biol. Chem.,
January 23, 2004;
279(4):
2394 - 2402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Ozanne, M. E. Brady, S. Cook, L. Gaughan, D. E. Neal, and C. N. Robson
Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin
Mol. Endocrinol.,
October 1, 2000;
14(10):
1618 - 1626.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. Benndorf, X. Sun, R. R. Gilmont, K. J. Biederman, M. P. Molloy, C. W. Goodmurphy, H. Cheng, P. C. Andrews, and M. J. Welsh
HSP22, a New Member of the Small Heat Shock Protein Superfamily, Interacts with Mimic of Phosphorylated HSP27 (3DHSP27)
J. Biol. Chem.,
July 13, 2001;
276(29):
26753 - 26761.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|